Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
Mené à partir d'échantillons sanguins prélevés sur 76 patients atteints d'un cancer du poumon non à petites cellules et non épidermoïde de stade IV et devant recevoir une chimiothérapie de première ligne par carboplatine ou cisplatine en combinaison avec le pémétrexed (âge médian : 66 ans), cet essai évalue la performance d'un test protéomique par spectrométrie de masse pour prédire la survie des patients
Background : VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of carboplatin or cisplatin with pemetrexed.
Methods : The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline. The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS) and objective response. Exploratory analyses of end points separately in carboplatin/pemetrexed and cisplatin/pemetrexed subgroups were also conducted.
Results : Patients classified as VeriStrat Good had longer PFS and OS than VeriStrat Poor: 6.5 vs 1.6 months and 10.8 vs 3.4 months, respectively; the corresponding hazard ratios (HRs) were 0.36 (P<0.0001) and 0.26 (P<0.0001); they were also more likely to achieve objective response. Prognostic significance of VeriStrat was confirmed in multivariate analysis. Significant differences in OS and PFS between Veristrat classifications were also found when treatment subgroups were analysed separately.
Conclusions : The trial demonstrated clinical utility of VeriStrat as a prognostic test for standard first-line chemotherapy of non-squamous advanced NSCLC.
British Journal of Cancer , résumé, 2015